Literature DB >> 17236249

Determination of atractylenolide II in rat plasma by reversed-phase high-performance liquid chromatography.

Jian Ge1, You-Wei Wang, Xiao-Cong Lu, Xiao-Hong Sun, Fu-Jun Gong.   

Abstract

A method for quantitative determination of atractylenolide II in rat plasma using reversed-phase high-performance liquid chromatography (RP-HPLC) coupled with UV spectrometry was established. From a variety of compounds and solvents tested, atractylenolide III was selected as the internal standard (IS) and ethyl acetate was found to be the best solvent for extracting atractylenolide II from plasma samples. RP-HPLC analysis of the extracts was performed on an analytical column (DIKMA ODS, 150 x 4.6 mm; i.d., 5 microm) equipped with a security guard pre-column system. There was good linearity over the range 0.05-5.0 microg/mL (r > 0.99). The recoveries were more than 90.0% in plasma, and the intra- and inter-day coefficients of variation were less than 10.0% in all cases. The limit of detection (LOD) was 0.025 microg/mL and the lower limit of quantification (LLOQ) was 0.05 microg/mL. The RP-HPLC method was applied to quantitate atractylenolide II in rat plasma within 24 h in a pharmacokinetics study where experimental rats received a single dose of atractylenolide II (60 mg/kg).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17236249     DOI: 10.1002/bmc.756

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  2 in total

1.  Chemical and ecological evaluation of a genuine Chinese medicine: Atractylodes macrocephala Koidz.

Authors:  Jue Zhou; Fan Qu; Yongping Yu
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-06-01

2.  Using UPLC-MS/MS for Characterization of Active Components in Extracts of Yupingfeng and Application to a Comparative Pharmacokinetic Study in Rat Plasma after Oral Administration.

Authors:  Meng-Qi Jia; Ye-Juan Xiong; Yun Xue; Yan Wang; Chao Yan
Journal:  Molecules       Date:  2017-05-17       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.